Ibex's Galen™ AI-powered platform is recognized by the FDA as breakthrough technology with the potential to more effectively diagnose cancer
The study was led by Dr. Liron Pantanowitz and Dr. Rajiv Dhir, pathologists at UPMC Shadyside Hospital, who provided blinded whole slide images of prostate core needle biopsies for analysis by Ibex's Galen™ Prostate solution.
With this CE-IVD Mark of Galen Prostate, Ibex is now partnering with leading institutes across Europe to implement AI and support pathologists in their diagnostic workflow.
The system uses an artificial intelligence (AI) powered algorithm to analyse cases in parallel to pathologists and compares between the pathologists' diagnoses and the algorithm's findings, subsequently alerting in case of discrepancies with high clinical importance (e.g. a missed cancer).
Ibex Medical Analytics Deploys the First Ever AI-based Digital Pathology Cancer Diagnosis System in Live Clinical Setting, With Immediate Impact on Patient Care
4/16/18: The system aims to eliminate errors in diagnosing prostate cancer.